title: Procedural and clinical evaluation of the novel zotarolimus-eluting resolute stent in patients with unselected bifurcated coronary stenosis treated by provisional approach: a multicenter registry.
abstract: OBJECTIVE
  As data on the use of the latest-generation drugeluting stents (DES) in bifurcation interventions are lacking, we realized a multicenter registry to assess the procedural and clinical results obtained in patients with unselected bifurcated lesions treated with the novel zotarolimus-eluting Resolute stent (ZRS).
  
  
  RESULTS
  Three Italian centers participated in the study. Consecutive patients with significant stenosis of bifurcated lesions undergoing DES implantation were treated with ZRS. The recommended technique was the "provisional TAP approach" [main-vessel (MV) stent implantation eventually followed by kissing balloon and sidebranch (SB) stenting according to TAP technique]. Clinical characteristics, procedural details and clinical follow-up data were prospectively recorded. Procedural success was defined as post-percutaneous coronary intervention visual stenosis > 20% on MV and TIMI 3 flow on both MV and SB. Primary endpoint was major adverse coronary events (cardiac death, myocardial infarction and target vessel revascularization) at 9-month follow up. A total of 180 patients were enrolled. The target lesion was located in the distal left main in 16% and in the left anterior descending artery in 52%. All but 3 cases were treated according to the provisional TAP approach (kissing balloon rate, 69%; overall SB stenting rate, 10.6%). Procedural success was obtained in 98.3% (3 failures due to final SB TIMI flow < 3). At 9-month follow up, the survival free from MACE was 97.8% (1 cardiac death and 3 repeat revascularizations).
  
  
  CONCLUSIONS
  The use of the latest-generation ZRS in unselected bifurcated lesions treated by a provisional approach is associated with excellent procedural results and with promising clinical outcomes.
authors.affiliation: Cardiovascular Department, Catholic University of Sacred Heart, Rome, Italy.
authors.forename: Antonella
authors.initials: A
authors.lastname: Tommasino
authors.forename: Francesco
authors.initials: F
authors.lastname: Burzotta
authors.forename: Alessandro
authors.initials: A
authors.lastname: Sciahbasi
authors.forename: Carlo
authors.initials: C
authors.lastname: Trani
authors.forename: Maria
authors.initials: M
authors.lastname: De Vita
authors.forename: Enrico
authors.initials: E
authors.lastname: Romagnoli
authors.forename: Ernesto
authors.initials: E
authors.lastname: Lioy
authors.forename: Fabio
authors.initials: F
authors.lastname: Tarantino
authors.forename: Francesco
authors.initials: F
authors.lastname: Summaria
authors.forename: Antonio Maria
authors.initials: AM
authors.lastname: Leone
authors.forename: Italo
authors.initials: I
authors.lastname: Porto
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Niccoli
authors.forename: Rocco
authors.initials: R
authors.lastname: Mongiardo
authors.forename: Mario Attilio
authors.initials: MA
authors.lastname: Mazzari
authors.forename: Giovanni
authors.initials: G
authors.lastname: Schiavoni
authors.forename: Filippo
authors.initials: F
authors.lastname: Crea
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D023903:Coronary Restenosis / Q000453:epidemiology; D023921:Coronary Stenosis / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007558:Italy; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: C489443:zotarolimus; D020123:Sirolimus